Cargando…

Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism

BACKGROUND/OBJECTIVE: Epithelial cell ovarian carcinomas rarely secrete steroid hormones, while sex cord and stromal cell ovarian carcinomas often do so. The objective of this report is to describe a patient with endometrioid ovarian carcinoma, an epithelial cell tumor, who presented with hyperandro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajamani, Krishnakumar, Moore, Richard G., Stanard, Sheena M., Astapova, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123561/
https://www.ncbi.nlm.nih.gov/pubmed/35602879
http://dx.doi.org/10.1016/j.aace.2022.01.003
_version_ 1784711578125336576
author Rajamani, Krishnakumar
Moore, Richard G.
Stanard, Sheena M.
Astapova, Olga
author_facet Rajamani, Krishnakumar
Moore, Richard G.
Stanard, Sheena M.
Astapova, Olga
author_sort Rajamani, Krishnakumar
collection PubMed
description BACKGROUND/OBJECTIVE: Epithelial cell ovarian carcinomas rarely secrete steroid hormones, while sex cord and stromal cell ovarian carcinomas often do so. The objective of this report is to describe a patient with endometrioid ovarian carcinoma, an epithelial cell tumor, who presented with hyperandrogenism due to testosterone production by the tumor. CASE REPORT: A 67-year-old postmenopausal woman with no history of endometriosis presented with new onset of hirsutism. Her testosterone level was 282 ng/dL (8-60 ng/dL), estradiol level was 72 pg/mL (≤32.2 pg/mL), and 17-hydroxyprogesterone level was 592 ng/dL (≤45 ng/dL). Pelvic ultrasound showed a right adnexal mass measuring 14.7 × 9.7 × 12.3 cm and an endometrial thickness of 9 mm with calcifications within the endometrium. Human epididymis protein 4 level was 210 pmol/L (0-140 pmol/L), and cancer antigen 125 level was 144 U/mL (0-34 U/mL). The patient underwent exploratory laparotomy with removal of the pelvic mass. Pathology showed an endometrioid adenocarcinoma with positive immunohistochemistry staining for the following steroidogenic enzymes: side-chain cleavage enzyme, 17α-hydroxylase, and aromatase. There was no evidence of tumor metastases within the pelvic cavity. Ovarian tumor markers normalized and remained stable 1 year after surgery. DISCUSSION: Although endometrioid ovarian carcinomas do not typically produce clinically significant levels of sex steroids, in rare cases, these tumors can do so, leading to symptoms and promoting early detection and treatment of the cancer. CONCLUSION: Sex hormone secretion by epithelial cell ovarian carcinomas should be considered in cases of new-onset steroid hormone excess in postmenopausal women.
format Online
Article
Text
id pubmed-9123561
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association of Clinical Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-91235612022-05-21 Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism Rajamani, Krishnakumar Moore, Richard G. Stanard, Sheena M. Astapova, Olga AACE Clin Case Rep Case Report BACKGROUND/OBJECTIVE: Epithelial cell ovarian carcinomas rarely secrete steroid hormones, while sex cord and stromal cell ovarian carcinomas often do so. The objective of this report is to describe a patient with endometrioid ovarian carcinoma, an epithelial cell tumor, who presented with hyperandrogenism due to testosterone production by the tumor. CASE REPORT: A 67-year-old postmenopausal woman with no history of endometriosis presented with new onset of hirsutism. Her testosterone level was 282 ng/dL (8-60 ng/dL), estradiol level was 72 pg/mL (≤32.2 pg/mL), and 17-hydroxyprogesterone level was 592 ng/dL (≤45 ng/dL). Pelvic ultrasound showed a right adnexal mass measuring 14.7 × 9.7 × 12.3 cm and an endometrial thickness of 9 mm with calcifications within the endometrium. Human epididymis protein 4 level was 210 pmol/L (0-140 pmol/L), and cancer antigen 125 level was 144 U/mL (0-34 U/mL). The patient underwent exploratory laparotomy with removal of the pelvic mass. Pathology showed an endometrioid adenocarcinoma with positive immunohistochemistry staining for the following steroidogenic enzymes: side-chain cleavage enzyme, 17α-hydroxylase, and aromatase. There was no evidence of tumor metastases within the pelvic cavity. Ovarian tumor markers normalized and remained stable 1 year after surgery. DISCUSSION: Although endometrioid ovarian carcinomas do not typically produce clinically significant levels of sex steroids, in rare cases, these tumors can do so, leading to symptoms and promoting early detection and treatment of the cancer. CONCLUSION: Sex hormone secretion by epithelial cell ovarian carcinomas should be considered in cases of new-onset steroid hormone excess in postmenopausal women. American Association of Clinical Endocrinology 2022-01-25 /pmc/articles/PMC9123561/ /pubmed/35602879 http://dx.doi.org/10.1016/j.aace.2022.01.003 Text en © 2022 AACE. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Rajamani, Krishnakumar
Moore, Richard G.
Stanard, Sheena M.
Astapova, Olga
Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism
title Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism
title_full Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism
title_fullStr Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism
title_full_unstemmed Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism
title_short Testosterone-Secreting Endometrioid Ovarian Carcinoma Presenting With Hyperandrogenism
title_sort testosterone-secreting endometrioid ovarian carcinoma presenting with hyperandrogenism
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123561/
https://www.ncbi.nlm.nih.gov/pubmed/35602879
http://dx.doi.org/10.1016/j.aace.2022.01.003
work_keys_str_mv AT rajamanikrishnakumar testosteronesecretingendometrioidovariancarcinomapresentingwithhyperandrogenism
AT moorerichardg testosteronesecretingendometrioidovariancarcinomapresentingwithhyperandrogenism
AT stanardsheenam testosteronesecretingendometrioidovariancarcinomapresentingwithhyperandrogenism
AT astapovaolga testosteronesecretingendometrioidovariancarcinomapresentingwithhyperandrogenism